BWAY Brainsway
- 6.620
- +0.330+5.25%
- 6.690
- +0.070+1.06%
Brainsway News
BrainsWay Analyst Ratings
Buy Rating Affirmed for Brainsway Following Strong Financial Performance and Strategic Advancements
BrainsWay Analyst Ratings
Buy Rating and Raised Price Target for Brainsway Reflecting Strong Financial Growth and Expansion Potential
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
Analysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)
BrainsWay Analyst Ratings
Oppenheimer Adjusts Price Target on Brainsway to $6 From $5.50, Maintains Outperform Rating
Oppenheimer Keeps Their Buy Rating on Brainsway (BWAY)
BrainsWay Analyst Ratings
Promising Outcomes From Accelerated Deep TMS Treatment Study Bolsters Buy Rating for Brainsway
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $12 Price Target
BrainsWay Analyst Ratings
Brainsway's Potential Market Expansion and Growth: A Buy Rating Justified by Strategic Growth, High-Impact Technology, and Promising Financial Outlook
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM) and Brainsway (BWAY)
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $12 Price Target
BrainsWay Analyst Ratings
Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR) and Brainsway (BWAY)
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $12 Price Target
BrainsWay Analyst Ratings
Analysis
Price Target
No Data
